AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Verastem shares rise 3.92% in after-hours after positive Phase 1 FRAME study results for avutometinib and defactinib combination therapy.
ByAinvest
Wednesday, Jul 2, 2025 4:51 pm ET1min read
Verastem, Inc. surged 3.92% in after-hours trading, following the publication of Phase 1 FRAME study results in Nature Medicine, showing a 42.3% overall response rate and a median progression-free survival of 20.1 months for low-grade serous ovarian cancer patients treated with avutometinib and defactinib. The response rate increased to 58.3% for KRAS-mutated patients, with a median progression-free survival of 30.8 months.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet